IPR's loss widened 70% to NZ$280.1m as operating outflow more than tripled

What changed

Interest income, the only revenue line, rose 131.9% to NZ$26.1m (FY22: NZ$11.3m), reflecting a substantially larger cash balance earning at higher rates. Despite that, the reported loss widened from NZ$164.7m to NZ$280.1m, a 70.1% deterioration. EBITDA (-NZ$280.1m) sits almost exactly on PBT (-NZ$280.1m) and NPAT (-NZ$280.1m), indicating that depreciation, interest and tax are immaterial and the loss is driven by items captured above the EBITDA line — consistent with fair-value movements on investments rather than operating cost growth.

Operating cash outflow worsened sharply to NZ$407.8m from NZ$119.1m (-242.3%). Yet closing cash jumped to NZ$382.1m from NZ$21.7m, funded by a disclosed investing inflow of roughly NZ$768.2m — i.e. realisations from the investment portfolio. Total assets fell 14.6% to NZ$1.738bn and equity fell by NZ$280.1m to NZ$1.626bn, in line with the loss. No borrowings are disclosed. No dividend was declared.

What matters

• The loss is a portfolio mark, not an operating cost blow-out. With EBITDA and PBT essentially identical and revenue rising, the NZ$115.5m deterioration in PBT almost certainly reflects fair-value losses on investments held. This makes the headline loss a function of asset marks rather than run-rate operating performance.
• Liquidity has been rebuilt, but through disposals. Cash is now 22% of total assets versus 1% a year ago. That reset came from the ~NZ$768.2m investing inflow, which — alongside the asset-base contraction to NZ$1.738bn — implies the portfolio has been materially de-risked or rotated, rather than funded from operating earnings.
• Strategy remains undefined in quantitative terms. The only forward statement is that the company "continues to look for appropriate acquisition targets" with majority-shareholder support. There is no target, no deployment timeline, and no disclosed pipeline.

Expectations

No stated financial targets, guidance or forward-work metrics were provided, so the result cannot be benchmarked against a numerical plan. Half-year shape shows the second half produced 60.6% of annual interest income (NZ$15.8m implied H2 vs NZ$10.3m H1), consistent with cash building through the period. The H2 EBITDA loss of NZ$147.7m was slightly larger than H1's NZ$132.3m, indicating marks continued to deteriorate into year-end rather than abating. Beyond that, the release does not support any inference about FY24 earnings power, redeployment timing, or return expectations.

Quality of result

Very little of the bottom-line movement looks durable or operating-driven. The interest-income line is genuine and scales with cash balances, but at NZ$26.1m it is an order of magnitude smaller than the NZ$280.1m loss. The loss itself is dominated by items running through EBITDA without a disclosed reconciliation bridge — most plausibly unrealised or realised fair-value losses. Cash conversion deteriorated materially: the NZ$288.7m worsening in operating cash outflow is roughly 2.5x the incremental accounting loss, indicating that cash losses were larger than the P&L suggests. The equity base has been absorbing these losses directly (NZ$1.906bn → NZ$1.626bn). ROE of -15.9% is, by itself, a weak read on capital efficiency for a fund-style vehicle.

Unresolved

• What specific investments drove the NZ$280.1m loss, and how much was realised versus unrealised at balance date?
• What was sold to generate the ~NZ$768.2m investing inflow, and at what exit multiples versus carrying value?
• With NZ$382.1m of cash and no stated acquisition pipeline, what is the redeployment horizon, and what return hurdle governs it?
• Why is there no formal EBITDA-to-NPAT bridge or breakdown of "other items" in what is disclosed?
• Is the majority-shareholder support structural (committed funding) or merely directional?

This briefing cannot assess portfolio composition, mark-to-market methodology, or the economic quality of any individual investment within IPR's asset base.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.